A Study to Learn About the Study Medicine Aztreonam-Avibactam (ATM-AVI) in Infants and Newborns Admitted in Hospitals With Bacterial Infection (CHERISH)

← catalyst calendar

NCT06462235 · readout in 249 d

Sponsored by Pfizer (industry) · PFE — their whole pipeline →. With AbbVie.

Phase

Phase 2

Status

Recruiting

Study type

Interventional

Design

Non randomized · None · Basic science

Enrollment

48estimated

Sites

Countries

Argentina, India, Israel +2

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2024-09-25

actual

When the study began enrolling

Primary completion

2027-04-25

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2027-04-25

estimated

The whole study's end, after follow-up

First posted

2024-06-17

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-06-11

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Gram-negative Bacterial Infection

Interventions

Drug: Part A: ATM-AVI Single Dose, Cohorts 1-4
Drug: Part B: Multiple-dose ATM-AVI, Cohorts 1-4

Primary outcomes

what the primary-completion date above is the date OF

Maximum Predicted Plasma Concentration (Cmax) of ATM and AVI

measured Up to Day 15

Area under the Concentration-Time Curve (AUC) of ATM-AVI

measured Up to Day 15

Plasma Elimination Half-Life (t1/2)

measured Up to Day 15

Apparent Clearance (CL)

measured Up to Day 15

Plasma concentrations of ATM and AVI by nominal sampling time

measured Up to Day 15

Proportion of Participants reporting Adverse Events (AE)